Abstract
The efficacy of PTH suppression of oral 1,25 (OH) (2)D(3) pulse therapy was greater in the group with well-controlled phosphate levels (mean serum P<6.0 mg/dl) in hemodialysis patients with secondary hyperparathyroidism. The restriction of dietary phosphate can decrease the level of serum phosphate without increasing the dose of phosphate binders and continue the treatment without increasing Ca x P product. The dietary phosphate reduction is important in oral 1,25 (OH) (2)D(3) pulse therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
